相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1839
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- University of Missouri researchers identified the protein TG2 as a contributor to arterial stiffening and inflammation, opening a new avenue for preventing and treating hypertension before it leads to heart attacks or strokes. - In a mouse study, removing TG2 from myeloid cells blunted angiotensin II-induced increases in blood pressure, arterial stiffness, and inflammation compared with mice retaining normal TG2 levels. - The findings suggest that blocking TG2 activity in myeloid cells could one day offer a more precise treatment for high blood pressure by reducing inflammation, potentially with fewer side effects. - The study, which focused on female mice, was published in the American Journal of Physiology and supported by the U.S. Department of Veterans Affairs.
- University of Missouri researchers have received a five-year, $2.8 million NIH R01 grant to investigate the first potential drug treatment for aortic valve calcification. - The team, led by Dunpeng Cai, found that patients with aortic valve calcification have elevated levels of the immune-regulating protein DOCK2 within aortic valve cells. - The research will test whether blocking DOCK2 with a drug compound can slow, stop, or reverse calcium buildup in the aortic valve using animal models. - If successful, Cai plans to advance a promising drug compound into clinical trials through the Roy Blunt NextGen Precision Health building.
- University of Missouri researchers found that shifting night rotations from 10 p.m.–6 a.m. to 8 p.m.–4 a.m. improved sleep quality and reduced inflammatory biomarkers in emergency medicine physicians. - White blood cell count and platelet count, both markers of inflammation, decreased after physicians adopted the earlier schedule, suggesting reduced inflammation. - Physicians reported more restorative sleep, more daytime hours for family and social engagements, and meaningful improvements in overall quality of life. - Researchers plan larger studies to determine whether the scheduling change benefits nurses and other overnight health care employees.
- Researchers at Washington University School of Medicine discovered that ETEC and Shigella rely on three closely related enzymes — EatA, SepA, and Pic — to penetrate the gut's protective mucus layer and cause infection. - Antibodies targeting a shared region of these enzymes were shown to neutralize all three, blocking the bacteria from breaching the intestinal mucus barrier, based on samples from infected patients and controlled human challenge studies. - Cryo-electron microscopy performed at the University of Missouri pinpointed the precise binding site of the most effective neutralizing antibodies, establishing a foundation for rational vaccine design. - The findings, published June 15 in PNAS, suggest a single combination vaccine could protect against multiple major causes of severe diarrhea, addressing a long-standing unmet need for children in endemic regions and travelers worldwide.
- The University of Missouri School of Medicine and MU Health Care have launched their first clinical trial using Eye90 microspheres manufactured on campus at the university's research reactor for treating unresectable liver tumors. - Eye90 microspheres are radiopaque glass beads embedded with yttrium-90 radioisotope, engineered for precise visualization during delivery to accurately target liver tumors while minimizing exposure to healthy tissue. - The clinical trial represents a major advancement in radiopharmaceutical capabilities at Mizzou, with the University of Missouri Research Reactor serving as the only domestic source of Y-90 in the United States. - The study involves single administration of microspheres followed by year-long monitoring to assess patient outcomes, with ABK Biomedical having previously initiated similar studies internationally.
- Bayer's investigational MRI contrast agent gadoquatrane met primary and secondary endpoints in the QUANTI Pediatric study, demonstrating similar pharmacokinetic behavior in children as observed in adults. - The study evaluated gadoquatrane at a 60% reduced gadolinium dose of 0.04 mmol Gd/kg body weight compared to standard macrocyclic contrast agents, potentially reducing lifetime gadolinium exposure in pediatric patients. - Based on positive results from the complete QUANTI program involving 808 patients across 15 countries, Bayer has submitted marketing authorization applications worldwide, including in the U.S., EU, Japan, and China. - If approved, gadoquatrane would become the lowest dose macrocyclic gadolinium-based contrast agent available, addressing the need for reduced exposure in patients requiring multiple MRI examinations.
- Researchers have developed a portable AI system that analyzes motor function to detect mild cognitive impairment with 83% accuracy, potentially enabling earlier intervention for dementia and Alzheimer's disease. - A new peel-and-sniff test shows that older adults with mild cognitive impairment score significantly lower on odor identification and memory tasks compared to those with normal brain function. - Both screening methods are designed to be cost-effective and accessible, with potential applications in various healthcare settings including clinics, senior centers, and assisted living facilities.
- The AVMA Veterinary Clinical Trials Registry lists studies for animal health, connecting researchers with veterinarians and owners. - North Carolina State University is exploring a novel treatment approach for oral cancer in cats. - Several studies are investigating canine cancers, including hemangiosarcoma, osteosarcoma, and mast cell tumors, with innovative therapies. - Research is underway to assess treatments for canine cognitive dysfunction and degenerative myelopathy, mirroring human neurological conditions.
